1
|
Choi JSY, de Haan JB, Sharma A. Animal models of diabetes-associated vascular diseases: an update on available models and experimental analysis. Br J Pharmacol 2021; 179:748-769. [PMID: 34131901 DOI: 10.1111/bph.15591] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 03/08/2021] [Accepted: 06/01/2021] [Indexed: 12/19/2022] Open
Abstract
Diabetes is a chronic metabolic disorder associated with the accelerated development of macrovascular (atherosclerosis and coronary artery disease) and microvascular complications (nephropathy, retinopathy and neuropathy), which remain the principal cause of mortality and morbidity in this population. Current understanding of cellular and molecular pathways of diabetes-driven vascular complications, as well as therapeutic interventions has arisen from studying disease pathogenesis in animal models. Diabetes-associated vascular complications are multi-faceted, involving the interaction between various cellular and molecular pathways. Thus, the choice of an appropriate animal model to study vascular pathogenesis is important in our quest to identify innovative and mechanism-based targeted therapies to reduce the burden of diabetic complications. Herein, we provide up-to-date information on available mouse models of both Type 1 and Type 2 diabetic vascular complications as well as experimental analysis and research outputs.
Collapse
Affiliation(s)
- Judy S Y Choi
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
| | - Judy B de Haan
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.,Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.,Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, Victoria, Australia.,Faculty of Science, Engineering and Technology, Swinburne University, Melbourne, Victoria, Australia.,Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Victoria, Australia
| | - Arpeeta Sharma
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.,Department of Diabetes, Monash University, Central Clinical School, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Li S, Sun X, Zhao Y, Wang X, Ji X, Sang S, Shao S, Xiang Y, Wang G, Lv M, Xue F, Sun Q, Du Y. Association Between Metabolic Syndrome and Asymptomatic Cerebral Arterial Stenosis: A Cross-Sectional Study in Shandong, China. Front Neurol 2021; 12:644963. [PMID: 34054693 PMCID: PMC8149894 DOI: 10.3389/fneur.2021.644963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 04/08/2021] [Indexed: 11/13/2022] Open
Abstract
Metabolic syndrome (MetS) can worsen cerebral arterial atherosclerosis stenosis in patients with stroke; however, its effect on patients without stroke remains ambiguous. This study explored the association of MetS and its individual components with asymptomatic intracranial arterial stenosis (aICAS) and asymptomatic extracranial arterial stenosis (aECAS) among older Chinese adults. A total of 1988 participants from the Kongcun Town study aged ≥40 years and without a history of stroke were enrolled. The baseline data were obtained via face-to-face interviews. MetS was defined according to International Diabetes Federation criteria. Detection of aICAS was conducted using transcranial Doppler ultrasound, followed by diagnosis via magnetic resonance angiography. The evaluation of aECAS was performed using bilateral carotid ultrasonography. The aICAS and aECAS groups were 1:1 matched separately to the non-stenosis group by age and sex. The association between MetS and aICAS or aECAS was analyzed using multivariate logistic regression. Among the 1988 participants, 909 were diagnosed with MetS. The prevalence of MetS was higher in the aICAS group than in the non-stenosis group (P <0.001), but did not differ significantly between the aECAS and non-stenosis groups. The prevalence of aICAS increased with the number of MetS components from 3.4% in the ≤ 1 component group to 12.7% in the ≥4 components group (P for trend <0.001). After adjusting for confounding factors, MetS components associated with aICAS included central obesity, elevated triglyceride levels, and elevated blood pressure. None of the MetS components was associated with aECAS. MetS was positively associated with aICAS, but not with aECAS. Further, different components play different roles in the pathological process leading to aICAS.
Collapse
Affiliation(s)
- Shan Li
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Xiao Sun
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Yuanyuan Zhao
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Xiang Wang
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Xiaokang Ji
- Department of Biostatistics, School of Public Health, Shandong University, Jinan, China
| | - Shaowei Sang
- Department of Clinical Epidemiology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China
| | - Sai Shao
- Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Yuanyuan Xiang
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Guangbin Wang
- Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Ming Lv
- Department of Clinical Epidemiology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China
| | - Fuzhong Xue
- Department of Biostatistics, School of Public Health, Shandong University, Jinan, China
| | - Qinjian Sun
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Yifeng Du
- Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.,Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| |
Collapse
|
3
|
Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets. Nutrients 2020; 12:nu12103130. [PMID: 33066385 PMCID: PMC7602228 DOI: 10.3390/nu12103130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 10/06/2020] [Accepted: 10/10/2020] [Indexed: 11/17/2022] Open
Abstract
Macronutrients represent risk factors for hyperlipidemia or diabetes. Lipid alterations and type 2 diabetes mellitus are global health problems. Overexpression of sterol regulatory element-binding factor (Srebf2) in transgenic animals is linked to elevated cholesterol levels and diabetes development. We investigated the impact of increased Srebf2 locus expression and the effects of control and high-fat, high-sucrose (HFHS) diets on body weight, glucose and lipid metabolisms in transgenic mice (S-mice). Wild type (WT) and S-mice were fed with both diets for 16 weeks. Plasma glucose, insulin and lipids were assessed (n = 25). Immunostainings were performed in liver, pancreas and fat (N = 10). Expression of Ldlr and Hmgcr in liver was performed by RT-PCR (N = 8). Control diet: S-mice showed reduced weight, insulin, total and HDL cholesterol and triglycerides (TG). HFHS diet widened differences in weight, total and HDL cholesterol, insulin and HOMA index but increased TG in S-mice. In S-mice, adipocyte size was lower while HFHS diet produced lower increase, pancreatic β-cell mass was lower with both diets and Srebf2, Ldlr and Hmgcr mRNA levels were higher while HFHS diet produced a rise in Srebf2 and Hmgcr levels. Srebf2 complete gene overexpression seems to have beneficial effects on metabolic parameters and to protect against HFHS diet effects.
Collapse
|
4
|
González-Ramos S, Fernández-García V, Recalde M, Rodríguez C, Martínez-González J, Andrés V, Martín-Sanz P, Boscá L. Deletion or Inhibition of NOD1 Favors Plaque Stability and Attenuates Atherothrombosis in Advanced Atherogenesis †. Cells 2020; 9:cells9092067. [PMID: 32927803 PMCID: PMC7564689 DOI: 10.3390/cells9092067] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 08/24/2020] [Accepted: 09/09/2020] [Indexed: 02/07/2023] Open
Abstract
Atherothrombosis, the main cause of acute coronary syndromes (ACS), is characterized by the rupture of the atherosclerotic plaque followed by the formation of thrombi. Fatal plaque rupture sites show large necrotic cores combined with high levels of inflammation and thin layers of collagen. Plaque necrosis due to the death of macrophages and smooth muscle cells (SMCs) remains critical in the process. To determine the contribution of the innate immunity receptor NOD1 to the stability of atherosclerotic plaque, Apoe-/- and Apoe-/- Nod1-/- atherosclerosis prone mice were placed on a high-fat diet for 16 weeks to assess post-mortem advanced atherosclerosis in the aortic sinus. The proliferation and apoptosis activity were analyzed, as well as the foam cell formation capacity in these lesions and in primary cultures of macrophages and vascular SMCs obtained from both groups of mice. Our results reinforce the preeminent role for NOD1 in human atherosclerosis. Advanced plaque analysis in the Apoe-/- atherosclerosis model suggests that NOD1 deficiency may decrease the risk of atherothrombosis by decreasing leukocyte infiltration and reducing macrophage apoptosis. Furthermore, Nod1-/- SMCs exhibit higher proliferation rates and decreased apoptotic activity, contributing to thicker fibrous caps with reduced content of pro-thrombotic collagen. These findings demonstrate a direct link between NOD1 and plaque vulnerability through effects on both macrophages and SMCs, suggesting promising insights for early detection of biomarkers for treating patients before ACS occurs.
Collapse
MESH Headings
- Animals
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Cells, Cultured
- Gene Deletion
- Humans
- Macrophages
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout, ApoE
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle
- Nod1 Signaling Adaptor Protein/physiology
- Plaque, Atherosclerotic/metabolism
- Plaque, Atherosclerotic/pathology
Collapse
Affiliation(s)
- Silvia González-Ramos
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain; (V.F.-G.); (M.R.); (P.M.-S.)
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
- Correspondence: (S.G.-R.); (L.B.); Tel.: +34-(0)91-497-2747 (ext. 5345) (L.B.)
| | - Victoria Fernández-García
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain; (V.F.-G.); (M.R.); (P.M.-S.)
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
| | - Miriam Recalde
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain; (V.F.-G.); (M.R.); (P.M.-S.)
| | - Cristina Rodríguez
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
- Institut de Recerca del Hospital de la Santa Creu i Sant Pau-Programa ICCC, IIB Sant Pau, 08041 Barcelona, Spain
| | - José Martínez-González
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
- Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), IIB Sant Pau, 08041 Barcelona, Spain
| | - Vicente Andrés
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain
| | - Paloma Martín-Sanz
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain; (V.F.-G.); (M.R.); (P.M.-S.)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain
| | - Lisardo Boscá
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain; (V.F.-G.); (M.R.); (P.M.-S.)
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (C.R.); (J.M.-G.); (V.A.)
- Correspondence: (S.G.-R.); (L.B.); Tel.: +34-(0)91-497-2747 (ext. 5345) (L.B.)
| |
Collapse
|
5
|
Herrero-Cervera A, Vinué Á, Burks DJ, González-Navarro H. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis. Diabetologia 2019; 62:2143-2157. [PMID: 31388695 DOI: 10.1007/s00125-019-4962-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 06/10/2019] [Indexed: 12/27/2022]
Abstract
AIMS/HYPOTHESIS Non-alcoholic fatty liver disease (NAFLD) is frequently associated with type 2 diabetes mellitus. Progression of NAFLD is mediated, among other things, by activation of inflammatory pathways. In the present study, the role of the proinflammatory cytokine LIGHT (TNFSF14) was explored in NAFLD and type 2 diabetes mellitus in mice deficient for the cytokine. METHODS Light-deficient (Light-/-) mice and WT controls were fed a regular chow diet (RCD) or a high-fat high-cholesterol diet (HFHCD) for 16 weeks. The expression of LIGHT and its receptors, herpes virus entry mediator (HVEM) and lymphotoxin β receptor (LTβR), was investigated in both dietary regimens. Glucose tolerance, insulin sensitivity, non-alcoholic fatty liver (NAFL), systemic and tissue inflammation, and metabolic gene expression were explored in Light-/- and WT mice fed an RCD and an HFHCD. The effect of Light deficiency was also evaluated in hepatic tissue and in inflammation in HFHCD-fed Irs2+/- mice with impaired insulin signalling. RESULTS Light deficiency did not have an effect on metabolism, in NAFL or in tissue and systemic inflammation, in RCD-fed WT mice. HVEM and LTβR were markedly increased in livers of HFHCD-fed WT mice compared with RCD-fed WT controls. In WT mice under HFHCD, Light deficiency improved glucose tolerance and insulin sensitivity. Non-alcoholic fatty liver disease activity (NAS) score, hepatic CD3+ T lymphocytes and F4/80+ macrophages were decreased in HFHCD-fed Light-/- mice compared with HFHCD-fed WT controls. Consistent with a potential role of adipose tissue in hepatic homeostasis, Light-/- mice exhibited augmented anti-inflammatory F4/80+CD206+ adipose tissue macrophages and reduced proinflammatory F4/80+CD11c+ adipose tissue macrophages. Moreover, adipose tissue explants from Light-/- mice showed diminished secretion of monocyte chemoattractant protein 1 (MCP1), TNF-α and IL-17 cytokines. Circulating Light-/- leucocytes consistently displayed augmented levels of the patrolling Ly6Clow monocytes, decreased Th9 T cell subset and diminished plasma TNF-α and IL-6 levels. Similarly, Light deficiency in Irs2+/- mice, which display impaired insulin signalling, also reduced NAFL as well as systemic and adipose tissue inflammation. Analysis of hepatic gene expression in Light-/- mouse livers showed reduced levels of Zbtb16, the transcription factor essential for natural killer T (NKT) cell function, and two genes related to NAFLD and fibrosis, Klf6 and Tlr4. CONCLUSIONS/INTERPRETATION These results indicate that Light deficiency in HFHCD improves hepatic glucose tolerance, and reduces hepatic inflammation and NAFL. This is accompanied by decreased systemic inflammation and adipose tissue cytokine secretion and by changes in the expression of key genes such as Klf6 and Tlr4 involved in NAFLD. These results suggest that therapies to block LIGHT-dependent signalling might be useful to restore hepatic homeostasis and to restrain NAFLD.
Collapse
Affiliation(s)
| | - Ángela Vinué
- INCLIVA Health Research Institute, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain
| | - Deborah J Burks
- The Prince Felipe Research Center (CIPF), Valencia, Spain
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain
| | - Herminia González-Navarro
- INCLIVA Health Research Institute, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.
- Department of Didactics of Experimental and Social Sciences, University of Valencia, Valencia, Spain.
| |
Collapse
|
6
|
Vila-Caballer M, González-Granado JM, Zorita V, Abu Nabah YN, Silvestre-Roig C, Del Monte-Monge A, Molina-Sánchez P, Ait-Oufella H, Andrés-Manzano MJ, Sanz MJ, Weber C, Kremer L, Gutiérrez J, Mallat Z, Andrés V. Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. J Mol Cell Cardiol 2019; 132:154-163. [PMID: 31121182 DOI: 10.1016/j.yjmcc.2019.05.009] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 05/12/2019] [Indexed: 12/23/2022]
Abstract
The CC chemokine 1 (CCL1, also called I-309 or TCA3) is a potent chemoattractant for leukocytes that plays an important role in inflammatory processes and diseases through binding to its receptor CCR8. Here, we investigated the role of the CCL1-CCR8 axis in atherosclerosis. We found increased expression of CCL1 in the aortas of atherosclerosis-prone fat-fed apolipoprotein E (Apoe)-null mice; moreover, in vitro flow chamber assays and in vivo intravital microscopy demonstrated an essential role for CCL1 in leukocyte recruitment. Mice doubly deficient for CCL1 and Apoe exhibited enhanced atherosclerosis in aorta, which was associated with reduced plasma levels of the anti-inflammatory interleukin 10, an increased splenocyte Th1/Th2 ratio, and a reduced regulatory T cell (Treg) content in aorta and spleen. Reduced Treg recruitment and aggravated atherosclerosis were also detected in the aortas of fat-fed low-density lipoprotein receptor-null mice treated with CCR8 blocking antibodies. These findings demonstrate that disruption of the CCL1-CCR8 axis promotes atherosclerosis by inhibiting interleukin 10 production and Treg recruitment and function.
Collapse
Affiliation(s)
- Marian Vila-Caballer
- Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain; Universidad Cardenal Herrera-CEU (CEU Universities), Valencia, Spain
| | - José M González-Granado
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain; LamImSys Laboratory, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Virginia Zorita
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Yafa N Abu Nabah
- Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain
| | - Carlos Silvestre-Roig
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany
| | - Alberto Del Monte-Monge
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain
| | | | - Hafid Ait-Oufella
- Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Cardiovascular Research Center, Paris, France
| | - María J Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain
| | - María J Sanz
- Departamento de Farmacología, Universidad de Valencia and Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany
| | - Leonor Kremer
- Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - Julio Gutiérrez
- Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - Ziad Mallat
- Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Cardiovascular Research Center, Paris, France; Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain.
| |
Collapse
|
7
|
Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus. Transl Res 2019; 203:31-48. [PMID: 30176239 DOI: 10.1016/j.trsl.2018.08.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 12/12/2022]
Abstract
Previous studies indicate a role of CDKN2A/2B/2BAS genes in atherosclerosis and type 2 diabetes mellitus (T2DM). Progression of these diseases is accompanied by T-cell imbalance and chronic inflammation. Our main objective was to investigate a potential association between CDKN2A/2B/2BAS gene expression and T cell phenotype in T2DM and coronary artery disease (CAD) in humans, and to explore the therapeutic potential of these genes to restore immune cell homeostasis and disease progression. Reduced mRNA levels of CDKN2A (p16Ink4a), CDKN2B (p15Ink4b), and CDKN2BAS were observed in human T2DM and T2DM-CAD subjects compared with controls. Protein levels of p16Ink4a and p15Ink4b were also diminished in T2DM-CAD patients while CDK4 levels, the main target of p16Ink4a and p15Ink4b, were augmented in T2DM and T2DM-CAD subjects. Both patient groups displayed higher activated CD3+CD69+ T cells and proatherogenic CD14++CD16+ monocytes, while CD4+CD25+CD127 regulatory T (Treg cells) cells were decreased. Treatment of primary human lymphocytes with PD0332991, a p16Ink4a/p15Ink4b mimetic drug and a proven CDK4 inhibitor, increased Treg cells and the levels of activated transcription factor phosphoSTAT5. In vivo PD0332991 treatment of atherosclerotic apoE-/- mice and insulin resistant apoE-/-Irs2+/- mice augmented Foxp3-expressing Treg cells and decreased lesion size. Thus, atherosclerosis complications in T2DM associate with altered immune cell homeostasis, diminished CDKN2A/2B/2BAS expression, and increased CDK4 levels. The present study also suggests that the treatment with drugs that mimic CDKN2A/2B genes could potential be considered as a promising therapy to delay atherosclerosis.
Collapse
|
8
|
Johnson C, Drummer C, Virtue A, Gao T, Wu S, Hernandez M, Singh L, Wang H, Yang XF. Increased Expression of Resistin in MicroRNA-155-Deficient White Adipose Tissues May Be a Possible Driver of Metabolically Healthy Obesity Transition to Classical Obesity. Front Physiol 2018; 9:1297. [PMID: 30369883 PMCID: PMC6194169 DOI: 10.3389/fphys.2018.01297] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 08/29/2018] [Indexed: 12/11/2022] Open
Abstract
We reported that microRNA-155 (miR-155) deficiency in ApoE-/- mice yields a novel metabolically healthy obese (MHO) model, which exhibits improved atherosclerosis but results in obesity, non-alcoholic fatty liver disease (NAFLD) without insulin resistance. Using experimental data mining approaches combined with experiments, we found that, among 109 miRNAs, miR-155, and miR-221 are significantly modulated in all four hyperlipidemia-related diseases (HRDs), namely atherosclerosis, NAFLD, obesity and type II diabetes (T2DM). MiR-155 is significantly upregulated in atherosclerosis and decreased in other HRDs. MiR-221 is increased in three HRDs but reduced in obesity. These findings led to our new classification of types I and II MHOs, which are regulated by miR-221 and miR-155, respectively. Western blots showed that the proinflammatory adipokine, resistin, is significantly increased in white adipose tissues (WAT) of the MHO mice, revealing our newly proposed, miR-155-suppressed “secondary wave inflammatory state (SWIS),” characteristic of MHO transition to classical obesity (CO). Taken together, we are first to show that MHO may have heterogeneity in comorbidities, and is therefore classified into type I, and type II MHOs; and that increased expression of resistin in miR-155-/- white adipose tissues may be a driver for SWIS in MHO transition to CO. Our findings provide novel insights into the pathogenesis of MHO, MHO transition to CO, hyperlipidemic pathways related to cancer, and new therapeutic targets.
Collapse
Affiliation(s)
- Candice Johnson
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Charles Drummer
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Anthony Virtue
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Tracy Gao
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Susu Wu
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Miguel Hernandez
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Lexy Singh
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Hong Wang
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| | - Xiao-Feng Yang
- Center for Metabolic Disease Research, Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States
| |
Collapse
|
9
|
Andrés-Blasco I, Vinué À, Herrero-Cervera A, Martínez-Hervás S, Nuñez L, Piqueras L, Ascaso JF, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathway. Thromb Haemost 2018; 116:379-93. [DOI: 10.1160/th15-10-0773] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 04/24/2016] [Indexed: 01/03/2023]
Abstract
SummaryCoexistence of insulin resistance (IR) and metabolic syndrome (MetS) increases the risk of cardiovascular disease (CVD). Genetic studies in diabetes have linked Hepatic Lipase (HL) to an enhanced risk of CVD while others indicate a role of HL in inflammatory cells. Thus, we explored the role of HL on atherosclerosis and inflammation in a mouse model of MetS/IR, (apoE-/-Irs2+/- mice) and in patients with MetS and IR. HL-deficiency in apoE-/-Irs2+/- mice reduced atheroma size, plaque vulnerability, leukocyte infiltration and macrophage proliferation. Compared with apoE-/-Irs2+/-HL+/+ mice, MCP1, TNFa and IL6 plasma levels, pro-inflammatory Ly6Chi monocytes and activated(CD69+)-T lymphocytes were also decreased in apoE-/-Irs2+/-HL-/- mice. The LIGHT (Tumour necrosis factor ligand superfamily member 14, TNFSF14)/ Lymphotoxin β-Receptor(LTβ-R) pathway, which is involved in T-cell and macrophage activation, was diminished in plasma and in apoE-/-Irs2+/-HL-/- mouse atheromas. Treatment of apoE-/-Irs2+/-HL-/- mice with LIGHT increased the number of Ly6Chi-monocytes and lesion size. Acutely LIGHT-treated apoE-/- mice displayed enhanced proliferating Ly6Chi-monocytes and increased activation of the mitogen-activated protein kinase p38, suggesting that LIGHT/LTβ-R axis might promote atherogenesis by increasing proinflammatory monocytes and proliferation. Notably, MetS-IR subjects with increased atherosclerosis displayed up-regulation of the LIGHT/LTβ-R axis, enhanced inflammatory monocytes and augmented HL mRNA expression in circulating leukocytes. Thus, HL-deficiency decreases atherosclerosis in MetS/IR states by reducing inflammation and macrophage proliferation which are partly attributed to reduced LIGHT/LTβ-R pathway. These studies identify the LIGHT/LTβ-R axis as a main pathway in atherosclerosis and suggest that its inactivation might ameliorate inflammation and macrophage proliferation associated with atherosclerosis burden in MetS/IR.Supplementary Material to this article is available at www.thrombosis-online.com.
Collapse
|
10
|
Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation. J Mol Cell Cardiol 2018; 116:5-15. [PMID: 29408196 DOI: 10.1016/j.yjmcc.2018.01.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 01/10/2018] [Accepted: 01/15/2018] [Indexed: 12/31/2022]
Abstract
Phosphorylation at serine 10 (S10) is the major posttranslational modification of the tumor suppressor p27, and is reduced in both human and mouse atherosclerosis. Moreover, a lack of p27-phospho-S10 in apolipoprotein E-null mice (apoE-/-) leads to increased high-fat diet-induced atherosclerosis associated with endothelial dysfunction and augmented leukocyte recruitment. In this study, we analyzed whether p27-phospho-S10 modulates additional endothelial functions and associated pathologies. Defective p27-phospho-S10 increases COX-2 activity in mouse aortic endothelial cells without affecting other key regulators of vascular reactivity, reduces endothelium-dependent dilation, and increases arterial contractility. Lack of p27-phospho-S10 also elevates aortic COX-2 expression and thromboxane A2 production, increases aortic lumen diameter, and aggravates angiotensin II-induced abdominal aortic aneurysm development in apoE-/- mice. All these abnormal responses linked to defective p27-phospho-S10 are blunted by pharmacological inhibition of COX-2. These results demonstrate that defective p27-phospho-S10 modifies endothelial behavior and promotes aneurysm formation via COX-2 activation.
Collapse
|
11
|
With mouse age comes wisdom: A review and suggestions of relevant mouse models for age-related conditions. Mech Ageing Dev 2016; 160:54-68. [DOI: 10.1016/j.mad.2016.07.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 07/07/2016] [Accepted: 07/15/2016] [Indexed: 12/14/2022]
|
12
|
Mori Y, Chiang S, Bendeck MP, Giacca A. Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice. Am J Physiol Endocrinol Metab 2016; 311:E335-45. [PMID: 27221119 DOI: 10.1152/ajpendo.00320.2015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 05/19/2016] [Indexed: 11/22/2022]
Abstract
It has been argued whether insulin accelerates or prevents atherosclerosis. Although results from in vitro studies have been conflicting, recent in vivo mice studies demonstrated antiatherogenic effects of insulin. Insulin is a known activator of endothelial nitric oxide synthase (NOS), leading to increased production of NO, which has potent antiatherogenic effects. We aimed to examine the role of NOS in the protective effects of insulin against atherosclerosis. Male apolipoprotein E-null mice (8 wk old) fed a high-cholesterol diet (1.25% cholesterol) were assigned to the following 12-wk treatments: control, insulin (0.05 U/day via subcutaneous pellet), N(ω)-nitro-l-arginine methyl ester hydrochloride (l-NAME, via drinking water at 100 mg/l), and insulin plus l-NAME. Insulin reduced atherosclerotic plaque burden in the descending aorta by 42% compared with control (plaque area/aorta lumen area: control, 16.5 ± 1.9%; insulin, 9.6 ± 1.3%, P < 0.05). Although insulin did not decrease plaque burden in the aortic sinus, macrophage accumulation in the plaque was decreased by insulin. Furthermore, insulin increased smooth muscle actin and collagen content and decreased plaque necrosis, consistent with increased plaque stability. In addition, insulin treatment increased plasma NO levels, decreased inducible NOS staining, and tended to increase phosphorylated vasodilator-stimulated phosphoprotein staining in the plaques of the aortic sinus. All these effects of insulin were abolished by coadministration of l-NAME, whereas l-NAME alone showed no effect. Insulin also tended to increase phosphorylated endothelial NOS and total neuronal NOS staining, effects not modified by l-NAME. In conclusion, we demonstrate that insulin treatment decreases atherosclerotic plaque burden and increases plaque stability through NOS-dependent mechanisms.
Collapse
Affiliation(s)
- Yusaku Mori
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Shinagawa, Tokyo, Japan
| | - Simon Chiang
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Michelle P Bendeck
- Department of Laboratory Medicine and Pathobiology, Ted Rogers Centre for Heart Research TBEP/ University of Toronto, Ontario, Canada; and
| | - Adria Giacca
- Department of Physiology and Medicine, Institute of Medical Science, Banting and Best Diabetes Centre, Toronto, Ontario, Canada
| |
Collapse
|
13
|
ATRQβ-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice. J Hypertens 2016; 34:474-85; discussion 485. [DOI: 10.1097/hjh.0000000000000835] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. J Endocrinol 2015; 227:179-91. [PMID: 26423094 DOI: 10.1530/joe-15-0219] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/30/2015] [Indexed: 12/15/2022]
Abstract
Metabolic syndrome and type 2 diabetes mellitus constitute a major problem to global health, and their incidence is increasing at an alarming rate. Non-alcoholic fatty liver disease, which affects up to 90% of obese people and nearly 70% of the overweight, is commonly associated with MetS characteristics such as obesity, insulin resistance, hypertension and dyslipidemia. In the present study, we demonstrate that hepatic lipase (HL)-inactivation in mice fed with a high-fat, high-cholesterol diet produced dyslipidemia including hypercholesterolemia, hypertriglyceridemia and increased non-esterified fatty acid levels. These changes were accompanied by glucose intolerance, pancreatic and hepatic inflammation and steatosis. In addition, compared with WT mice, HL(-/-) mice exhibited enhanced circulating MCP1 levels, monocytosis and higher percentage of CD4+Th17+ cells. Consistent with increased inflammation, livers from HL(-/-) mice had augmented activation of the stress SAPK/JNK- and p38-pathways compared with the activation levels of the kinases in livers from WT mice. Analysis of HL(-/-) and WT mice fed regular chow diet showed dyslipidemia and glucose intolerance in HL(-/-) mice without any other changes in inflammation or hepatic steatosis. Altogether, these results indicate that dyslipidemia induced by HL-deficiency in combination with a high-fat, high-cholesterol diet promotes hepatic steatosis and inflammation in mice which are, at least in part, mediated by the activation of the stress SAPK/JNK- and p38-pathways. Future studies are warranted to asses the viability of therapeutic strategies based on the modulation of these kinases to reduce hepatic steatosis associated to lipase dysfunction.
Collapse
Affiliation(s)
- Irene Andrés-Blasco
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Andrea Herrero-Cervera
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Ángela Vinué
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Sergio Martínez-Hervás
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Laura Piqueras
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - María Jesús Sanz
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Deborah Jane Burks
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| |
Collapse
|
15
|
El ratón deficiente en apolipoproteína E, un modelo traslacional para el estudio de la aterosclerosis. ANGIOLOGIA 2015. [DOI: 10.1016/j.angio.2015.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
16
|
Molina-Sánchez P, Chèvre R, Rius C, Fuster J, Andrés V. Loss of p27 phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte recruitment via RhoA/ROCK. J Mol Cell Cardiol 2015; 84:84-94. [DOI: 10.1016/j.yjmcc.2015.04.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Revised: 03/23/2015] [Accepted: 04/14/2015] [Indexed: 01/17/2023]
|
17
|
Vinué Á, Andrés-Blasco I, Herrero-Cervera A, Piqueras L, Andrés V, Burks DJ, Sanz MJ, González-Navarro H. Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling. Biochim Biophys Acta Mol Basis Dis 2015; 1852:1729-42. [PMID: 26022372 DOI: 10.1016/j.bbadis.2015.05.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 05/15/2015] [Accepted: 05/20/2015] [Indexed: 01/12/2023]
Abstract
Single nucleotide polymorphisms near the Ink4/Arf locus have been associated with type-2 diabetes mellitus. Previous studies indicate a protective role of the locus in the carbohydrate metabolism derangement associated with ageing in wild-type mice. The present study demonstrates that the increased Ink4/Arf locus expression in 1-year-old mice, partially-deficient for the insulin receptor substrate (IRS)2 (Irs2+/-SuperInk4/Arf mice) ameliorates hepatic steatosis, inflammation and insulin resistance. Irs2+/-SuperInk4/Arf mice displayed improved glucose tolerance and insulin sensitivity compared with Irs2+/- mice which were glucose intolerant and insulin resistant compared with age-matched wild-type mice. These changes in Irs2+/- mice were accompanied by enhanced hepatic steatosis, proinflammatory macrophage phenotype, increased Ly6C(hi)-monocyte percentage, T-lymphocyte activation and MCP1 and TNF-α cytokine levels. In Irs2+/-SuperInk4/Arf mice, steatosis and inflammatory parameters were markedly reduced and similar to those of wild-type counterparts. In vivo insulin signalling also revealed reduced activation of the IRS/AKT-dependent signalling in Irs2+/- mice. This was restored upon increased locus expression in Irs2+/-SuperInk4/Arf mice which display similar activation levels as those for wild-type mice. In vivo treatment of Irs2+/-SuperInk4/Arf mice with TNF-α diminished insulin canonical IRS/AKT-signalling and enhanced the stress SAPK/JNK-phosphoSer307IRS1-pathway suggesting that cytokine levels might potentially affect glucose homeostasis through changes in these insulin-signalling pathways. Altogether, these results indicate that enhanced Ink4/Arf locus expression restores glucose homeostasis and that this is associated with diminished hepatic steatosis and inflammation in mice with insulin resistance. Therefore, pharmacological interventions targeted to modulate the Ink4/Arf locus expression could be a tentative therapeutic approach to alleviate the inflammation associated with insulin resistance.
Collapse
Affiliation(s)
- Ángela Vinué
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain
| | | | | | - Laura Piqueras
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain
| | - Vicente Andrés
- Department of Atherothrombosis, Imaging and Epidemiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Deborah J Burks
- Centro de Investigación Príncipe Felipe (CIPF), 46012 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Spain
| | - María Jesús Sanz
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain; Departamento de Farmacología, Universidad de Valencia, 46010 Valencia, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Spain.
| |
Collapse
|
18
|
Elliott KJ, Eguchi S. Phosphorylation Regulation by Kinases and Phosphatases in Atherosclerosis. Atherosclerosis 2015. [DOI: 10.1002/9781118828533.ch35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
19
|
Abstract
In vivo metabolic tests are highly valuable to determine whether atherosclerosis progression in mouse models is accompanied by carbohydrate metabolism alterations such as glucose intolerance and insulin resistance. In this chapter, we describe protocols to perform in the mouse glucose and insulin tolerance tests, two metabolic assays which evaluate the glucose tolerance and the insulin sensitivity, respectively.
Collapse
Affiliation(s)
- Ángela Vinué
- Institute of Health Research-INCLIVA, C/Menéndez Pelayo, 4, 46010, Valencia, Spain
| | | |
Collapse
|
20
|
Heinonen SE, Genové G, Bengtsson E, Hübschle T, Åkesson L, Hiss K, Benardeau A, Ylä-Herttuala S, Jönsson-Rylander AC, Gomez MF. Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches. J Diabetes Res 2015; 2015:404085. [PMID: 25785279 PMCID: PMC4345079 DOI: 10.1155/2015/404085] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 01/26/2015] [Indexed: 12/19/2022] Open
Abstract
Diabetes mellitus is a lifelong, incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease, stroke, and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). Based on the current trends, the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. Therefore, novel means to prevent and treat these complications are needed. Under the auspices of the IMI (Innovative Medicines Initiative), the SUMMIT (SUrrogate markers for Micro- and Macrovascular hard end points for Innovative diabetes Tools) consortium is working on the development of novel animal models that better replicate vascular complications of diabetes and on the characterization of the available models. In the past years, with the high level of genomic information available and more advanced molecular tools, a very large number of models has been created. Selecting the right model for a specific study is not a trivial task and will have an impact on the study results and their interpretation. This review gathers information on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development.
Collapse
Affiliation(s)
- Suvi E. Heinonen
- Bioscience, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca R&D, 43183 Mölndal, Sweden
- *Suvi E. Heinonen:
| | - Guillem Genové
- Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden
| | - Eva Bengtsson
- Department of Clinical Sciences, Lund University Diabetes Centre (LUDC), Lund University, 20502 Malmö, Sweden
| | - Thomas Hübschle
- R&D Diabetes Division, Translational Medicine, Sanofi-Aventis, 65926 Frankfurt am Main, Germany
| | - Lina Åkesson
- Department of Clinical Sciences, Lund University Diabetes Centre (LUDC), Lund University, 20502 Malmö, Sweden
| | - Katrin Hiss
- R&D Diabetes Division, Translational Medicine, Sanofi-Aventis, 65926 Frankfurt am Main, Germany
| | - Agnes Benardeau
- Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland
| | - Seppo Ylä-Herttuala
- Pharmaceutical Division, pRED, CV and Metabolic Disease, Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Ann-Cathrine Jönsson-Rylander
- Bioscience, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca R&D, 43183 Mölndal, Sweden
| | - Maria F. Gomez
- Department of Clinical Sciences, Lund University Diabetes Centre (LUDC), Lund University, 20502 Malmö, Sweden
| |
Collapse
|
21
|
Rotllan N, Chamorro-Jorganes A, Araldi E, Wanschel AC, Aryal B, Aranda JF, Goedeke L, Salerno AG, Ramírez CM, Sessa WC, Suárez Y, Fernández-Hernando C. Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis. FASEB J 2014; 29:597-610. [PMID: 25392271 DOI: 10.1096/fj.14-262097] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Atherosclerosis is the major cause of death and disability in diabetic and obese subjects with insulin resistance. Akt2, a phosphoinositide-dependent serine-threonine protein kinase, is highly express in insulin-responsive tissues; however, its role during the progression of atherosclerosis remains unknown. Thus, we aimed to investigate the contribution of Akt2 during the progression of atherosclerosis. We found that germ-line Akt2-deficient mice develop similar atherosclerotic plaques as wild-type mice despite higher plasma lipids and glucose levels. It is noteworthy that transplantation of bone marrow cells isolated from Akt2(-/-) mice to Ldlr(-/-) mice results in marked reduction of the progression of atherosclerosis compared with Ldlr(-/-) mice transplanted with wild-type bone marrow cells. In vitro studies indicate that Akt2 is required for macrophage migration in response to proatherogenic cytokines (monocyte chemotactic protein-1 and macrophage colony-stimulating factor). Moreover, Akt2(-/-) macrophages accumulate less cholesterol and have an alternative activated or M2-type phenotype when stimulated with proinflammatory cytokines. Together, these results provide evidence that macrophage Akt2 regulates migration, the inflammatory response and cholesterol metabolism and suggest that targeting Akt2 in macrophages might be beneficial for treating atherosclerosis.
Collapse
Affiliation(s)
- Noemi Rotllan
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Aránzazu Chamorro-Jorganes
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Elisa Araldi
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Amarylis C Wanschel
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Binod Aryal
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Juan F Aranda
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Leigh Goedeke
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Alessandro G Salerno
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Cristina M Ramírez
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - William C Sessa
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Yajaira Suárez
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Carlos Fernández-Hernando
- *Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA; Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Departments of Medicine, Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, New York, USA; and Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
22
|
Martínez-Hervás S, Vinué Á, Núñez L, Andrés-Blasco I, Piqueras L, Real JT, Ascaso JF, Burks DJ, Sanz MJ, González-Navarro H. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 2014; 103:324-336. [DOI: 10.1093/cvr/cvu115] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
23
|
Bornfeldt KE. 2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis. Arterioscler Thromb Vasc Biol 2014; 34:705-14. [PMID: 24665124 DOI: 10.1161/atvbaha.113.301928] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Adults with diabetes mellitus are much more likely to have cardiovascular disease than those without diabetes mellitus. Genetically engineered mouse models have started to provide important insight into the mechanisms whereby diabetes mellitus promotes atherosclerosis. Such models have demonstrated that diabetes mellitus promotes formation of atherosclerotic lesions, progression of lesions into advanced hemorrhaged lesions, and that it prevents lesion regression. The proatherosclerotic effects of diabetes mellitus are driven in part by the altered function of myeloid cells. The protein S100A9 and the receptor for advanced glycation end-products are important modulators of the effect of diabetes mellitus on myelopoiesis, which might promote monocyte accumulation in lesions. Furthermore, myeloid cell expression of the enzyme acyl-CoA synthetase 1 (ACSL1), which converts long-chain fatty acids into their acyl-CoA derivatives, has emerged as causal to diabetes mellitus-induced lesion initiation. The protective effects of myeloid ACSL1-deficiency in diabetic mice, but not in nondiabetic mice, indicate that myeloid cells are activated by diabetes mellitus through mechanisms that play minor roles in the absence of diabetes mellitus. The roles of reactive oxygen species and insulin resistance in diabetes mellitus-accelerated atherosclerosis are also discussed, primarily in relation to endothelial cells. Translational studies addressing whether the mechanisms identified in mouse models are equally important in humans with diabetes mellitus will be paramount.
Collapse
Affiliation(s)
- Karin E Bornfeldt
- From the Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, and Department of Pathology, Diabetes and Obesity Center of Excellence, University of Washington, Seattle, WA
| |
Collapse
|
24
|
Miranda DN, Coletta DK, Mandarino LJ, Shaibi GQ. Increases in insulin sensitivity among obese youth are associated with gene expression changes in whole blood. Obesity (Silver Spring) 2014; 22:1337-44. [PMID: 24470352 PMCID: PMC4008712 DOI: 10.1002/oby.20711] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Accepted: 01/22/2014] [Indexed: 01/02/2023]
Abstract
OBJECTIVE Lifestyle intervention can improve insulin sensitivity in obese youth, yet few studies have examined the molecular signatures associated with these improvements. Therefore, the purpose of this study was to explore gene expression changes in whole blood that are associated with intervention-induced improvements in insulin sensitivity. METHODS Fifteen (7M/8F) overweight/obese (BMI percentile = 96.3 ± 1.1) Latino adolescents (15.0 ± 0.9 years) completed a 12-week lifestyle intervention that included weekly nutrition education and 180 minutes of moderate-vigorous exercise per week. Insulin sensitivity was estimated by an oral glucose tolerance test and the Matsuda Index. Global microarray analysis profiling from whole blood was performed to examine changes in gene expression and to explore biological pathways that were significantly changed in response to the intervention. RESULTS A total of 1,459 probes corresponding to mRNA transcripts (717 up, 742 down) were differentially expressed with a fold change ≥1.2. These genes were mapped within eight significant pathways identified, including insulin signaling, type 1 diabetes, and glycerophospholipid metabolism. Participants with increased insulin sensitivity exhibited five times the number of significant genes altered compared with nonresponders (1,144 vs. 230). CONCLUSIONS These findings suggest that molecular signatures from whole blood are associated with lifestyle-induced health improvements among high-risk Latino youth.
Collapse
Affiliation(s)
- Danielle N. Miranda
- Mayo Graduate School, Mayo Clinic, Rochester, MN
- Mayo/ASU Center for Metabolic and Vascular Biology, Arizona State University, Tempe, Arizona
| | - Dawn K. Coletta
- School of Life Science, Arizona State University, Tempe, AZ
- Mayo/ASU Center for Metabolic and Vascular Biology, Arizona State University, Tempe, Arizona
| | - Lawrence J. Mandarino
- School of Life Science, Arizona State University, Tempe, AZ
- Mayo/ASU Center for Metabolic and Vascular Biology, Arizona State University, Tempe, Arizona
| | - Gabriel Q. Shaibi
- Mayo/ASU Center for Metabolic and Vascular Biology, Arizona State University, Tempe, Arizona
- College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ
- Southwest Interdisciplinary Research Center, Arizona State University, Phoenix, AZ
| |
Collapse
|
25
|
Rensing KL, de Jager SC, Stroes ES, Vos M, Twickler MT, Dallinga-Thie GM, de Vries CJ, Kuiper J, Bot I, von der Thüsen JH. Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. Cardiovasc Res 2013; 101:277-87. [DOI: 10.1093/cvr/cvt252] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
26
|
Abstract
At least 468 individual genes have been manipulated by molecular methods to study their effects on the initiation, promotion, and progression of atherosclerosis. Most clinicians and many investigators, even in related disciplines, find many of these genes and the related pathways entirely foreign. Medical schools generally do not attempt to incorporate the relevant molecular biology into their curriculum. A number of key signaling pathways are highly relevant to atherogenesis and are presented to provide a context for the gene manipulations summarized herein. The pathways include the following: the insulin receptor (and other receptor tyrosine kinases); Ras and MAPK activation; TNF-α and related family members leading to activation of NF-κB; effects of reactive oxygen species (ROS) on signaling; endothelial adaptations to flow including G protein-coupled receptor (GPCR) and integrin-related signaling; activation of endothelial and other cells by modified lipoproteins; purinergic signaling; control of leukocyte adhesion to endothelium, migration, and further activation; foam cell formation; and macrophage and vascular smooth muscle cell signaling related to proliferation, efferocytosis, and apoptosis. This review is intended primarily as an introduction to these key signaling pathways. They have become the focus of modern atherosclerosis research and will undoubtedly provide a rich resource for future innovation toward intervention and prevention of the number one cause of death in the modern world.
Collapse
Affiliation(s)
- Paul N Hopkins
- Cardiovascular Genetics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
| |
Collapse
|
27
|
González-Navarro H, Vinué Á, Sanz MJ, Delgado M, Pozo MA, Serrano M, Burks DJ, Andrés V. Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging. Aging Cell 2013; 12:102-11. [PMID: 23107464 DOI: 10.1111/acel.12023] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2012] [Indexed: 11/30/2022] Open
Abstract
Recent genome-wide association studies have linked type-2 diabetes mellitus to a genomic region in chromosome 9p21 near the Ink4/Arf locus, which encodes tumor suppressors that are up-regulated in a variety of mammalian organs during aging. However, it is unclear whether the susceptibility to type-2 diabetes is associated with altered expression of the Ink4/Arf locus. In the present study, we investigated the role of Ink4/Arf in age-dependent alterations of insulin and glucose homeostasis using Super-Ink4/Arf mice which bear an extra copy of the entire Ink4/Arf locus. We find that, in contrast to age-matched wild-type controls, Super-Ink4/Arf mice do not develop glucose intolerance with aging. Insulin tolerance tests demonstrated increased insulin sensitivity in Super-Ink4/Arf compared with wild-type mice, which was accompanied by higher activation of the insulin receptor substrate (IRS)-PI3K-AKT pathway in liver, skeletal muscle and heart. Glucose uptake studies in Super-Ink4/Arf mice showed a tendency toward increased (18)F-fluorodeoxyglucose uptake in skeletal muscle compared with wild-type mice (P = 0.079). Furthermore, a positive correlation between glucose uptake and baseline glucose levels was observed in Super-Ink4/Arf mice (P < 0.008) but not in wild-type mice. Our studies reveal a protective role of the Ink4/Arf locus against the development of age-dependent insulin resistance and glucose intolerance.
Collapse
Affiliation(s)
| | - Ángela Vinué
- Vascular Biology Unit; Department of Molecular and Cellular Pathology and Therapy; Instituto de Biomedicina de Valencia (IBV); Spanish Council for Scientific Research (CSIC); Valencia; 46010; Spain
| | | | - Mercedes Delgado
- CAI Cartografía Cerebral; Instituto Pluridisciplinar; Universidad Complutense de Madrid; Madrid; 28040; Spain
| | - Miguel Angel Pozo
- CAI Cartografía Cerebral; Instituto Pluridisciplinar; Universidad Complutense de Madrid; Madrid; 28040; Spain
| | - Manuel Serrano
- Spanish National Cancer Research Center (CNIO); Madrid; 28029; Spain
| | - Deborah J. Burks
- CIBER de Diabetes y Enfermedades Metabolicas (CIBERDEM); Centro de Investigación Príncipe Felipe (CIPF); Valencia; 46012; Spain
| | - Vicente Andrés
- Laboratory of Molecular and Genetic Cardiovascular Pathophysiology; Department of Epidemiology, Atherothrombosis and Imaging; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Madrid; 28029; Spain
| |
Collapse
|
28
|
Mazzoccoli G, Dagostino MP, Fontana A, Grandone E, Favuzzi G, Tiscia G, Margaglione M, de Matthaeis A, Greco A, Vendemiale G. Influence of the Gly1057Asp variant of the insulin receptor substrate 2 (IRS2) on insulin resistance and relationship with epicardial fat thickness in the elderly. Exp Gerontol 2012; 47:988-93. [DOI: 10.1016/j.exger.2012.09.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2012] [Revised: 08/29/2012] [Accepted: 09/17/2012] [Indexed: 10/27/2022]
|
29
|
López-Cancio E, Galán A, Dorado L, Jiménez M, Hernández M, Millán M, Reverté S, Suñol A, Barallat J, Massuet A, Alzamora MT, Dávalos A, Arenillas JF. Biological Signatures of Asymptomatic Extra- and Intracranial Atherosclerosis. Stroke 2012; 43:2712-9. [DOI: 10.1161/strokeaha.112.661702] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Elena López-Cancio
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Amparo Galán
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Laura Dorado
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Marta Jiménez
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - María Hernández
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Mónica Millán
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Silvia Reverté
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Anna Suñol
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Jaume Barallat
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Anna Massuet
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Maria Teresa Alzamora
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Antonio Dávalos
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| | - Juan Francisco Arenillas
- From the Departments of Neurosciences (E.L.-C., L.D., M.J., M.H., M.M., S.R., A.S., A.D.) and Biochemistry (A.G., J.B.) and the Magnetic Resonance Unit (A.M.), Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; the Primary Healthcare Research Support Unit Metropolitana Nord, ICS-IDIAP Jordi Gol, Mataró, Barcelona, Spain (M.T.A.); and the Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain (J.F.A.)
| |
Collapse
|
30
|
Robinson KG, Nie T, Baldwin A, Yang E, Kiick KL, Akins RE. Differential effects of substrate modulus on human vascular endothelial, smooth muscle, and fibroblastic cells. J Biomed Mater Res A 2012; 100:1356-67. [PMID: 22374788 PMCID: PMC3351091 DOI: 10.1002/jbm.a.34075] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Revised: 01/05/2012] [Accepted: 01/06/2012] [Indexed: 12/18/2022]
Abstract
Regenerative medicine approaches offer attractive alternatives to standard vascular reconstruction; however, the biomaterials to be used must have optimal biochemical and mechanical properties. To evaluate the effects of biomaterial properties on vascular cells, heparinized poly(ethylene glycol) (PEG)-based hydrogels of three different moduli, 13.7, 5.2, and 0.3 kPa, containing fibronectin and growth factor were utilized to support the growth of three human vascular cell types. The cell types exhibited differences in attachment, proliferation, and gene expression profiles associated with the hydrogel modulus. Human vascular smooth muscle cells demonstrated preferential attachment on the highest-modulus hydrogel, adventitial fibroblasts demonstrated preferential growth on the highest-modulus hydrogel, and human umbilical vein endothelial cells demonstrated preferential growth on the lowest-modulus hydrogel investigated. Our studies suggest that the growth of multiple vascular cell types can be supported by PEG hydrogels and that different populations can be controlled by altering the mechanical properties of biomaterials.
Collapse
Affiliation(s)
- Karyn G. Robinson
- Tissue Engineering and Regenerative Medicine Laboratory, Nemours Biomedical Research, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA
| | - Ting Nie
- Department of Materials Science and Engineering, University of Delaware, 201 DuPont Hall, Newark, DE 19716, USA
| | - Aaron Baldwin
- Department of Materials Science and Engineering, University of Delaware, 201 DuPont Hall, Newark, DE 19716, USA
| | - Elaine Yang
- Tissue Engineering and Regenerative Medicine Laboratory, Nemours Biomedical Research, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA
| | - Kristi L. Kiick
- Department of Materials Science and Engineering, University of Delaware, 201 DuPont Hall, Newark, DE 19716, USA
- Delaware Biotechnology Institute, 15 Innovation Way, Newark, DE 19716, USA
| | - Robert E. Akins
- Tissue Engineering and Regenerative Medicine Laboratory, Nemours Biomedical Research, Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA
| |
Collapse
|
31
|
Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology 2012; 21:253-9. [PMID: 22492174 DOI: 10.1007/s10787-012-0133-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2012] [Accepted: 03/16/2012] [Indexed: 10/28/2022]
Abstract
This study evaluates the migratory potential of monocytes isolated from two groups of human subjects: naïve and non-naïve to Cannabis. Phytocannabinoids (pCB), the bioactive agents produced by the plant Cannabis, regulate the phenotype and function of immune cells by interacting with CB1 and CB2 receptors. It has been shown that agents influencing the phenotype of circulating monocytes influence the phenotype of macrophages and the outcome of immune responses. To date, nothing is known about the acute and long-term effects of pCB on human circulating monocytes. Healthy subjects were recruited for a single blood draw. Monocytes were isolated, fluorescently labeled and their migration quantified using a validated assay that employs near infrared fluorescence and modified Boyden chambers. CB1 and CB2 receptor mRNA expression was quantified by qPCR. Monocytes from all subjects (n = 10) responded to chemokine (c-c motif) ligand 2 (CCL2) and human serum stimuli. Acute application of pCB significantly inhibited both the basal and CCL2-stimulated migration of monocytes, but only in subjects non-naïve to Cannabis. qPCR analysis indicates that monocytes from subjects non-naïve to Cannabis express significantly more CB1 mRNA. The phenotype of monocytes isolated from subjects non-naïve to Cannabis is significantly different from monocytes isolated from subjects naïve to Cannabis. Only monocytes from subjects non-naïve to Cannabis respond to acute exposure to pCB by reducing their overall migratory capacity. Our study suggests that chronic exposure to Cannabis affects the phenotype of circulating monocytes and accordingly could influence outcome of inflammatory responses occurring in injured tissues.
Collapse
|
32
|
Rask-Madsen C, Buonomo E, Li Q, Park K, Clermont AC, Yerokun O, Rekhter M, King GL. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2012; 32:1124-31. [PMID: 22426129 DOI: 10.1161/atvbaha.111.239558] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To determine the contribution of hyperinsulinemia to atherosclerosis development. METHODS AND RESULTS Apolipoprotein E (Apoe) null mice that had knockout of a single allele of the insulin receptor (Insr) gene were compared with littermate Apoe null mice with intact insulin receptors. Plasma insulin levels in Insr haploinsufficient/Apoe null mice were 50% higher in the fasting state and up to 69% higher during a glucose tolerance test, but glucose tolerance was not different in the 2 groups. C-peptide levels, insulin sensitivity, and postreceptor insulin signaling in muscle, liver, fat, and aorta were not different between groups, whereas disappearance in plasma of an injected insulin analog was delayed in Insr haploinsufficient/Apoe null mice, indicating that impaired insulin clearance was the primary cause of hyperinsulinemia. No differences were observed in plasma lipids or blood pressure. Despite the hyperinsulinemia, atherosclerotic lesion size was not different between the 2 groups at time points up to 52 weeks of age when measured as en face lesion area in the aorta, cross-sectional plaque area in the aortic sinus, and cholesterol abundance in the brachiocephalic artery. CONCLUSIONS Hyperinsulinemia, without substantial vascular or whole-body insulin resistance and without changes in plasma lipids or blood pressure, does not change susceptibility to atherosclerosis.
Collapse
|
33
|
Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012; 271:294-304. [PMID: 21883535 DOI: 10.1111/j.1365-2796.2011.02442.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVES Insulin resistance is associated with increased CD36 expression in a number of tissues. Moreover, excess macrophage CD36 may initiate atherosclerotic lesions. The aim of this study was to determine whether plasma soluble CD36 (sCD36) was associated with insulin resistance, fatty liver and carotid atherosclerosis in nondiabetic subjects. METHODS In 1296 healthy subjects without diabetes or hypertension recruited from 19 centres in 14 European countries (RISC study), we determined the levels of sCD36, adiponectin, lipids and liver enzymes, insulin sensitivity (M/I) by euglycaemic-hyperinsulinaemic clamp, carotid atherosclerosis as intima-media thickness (IMT) and two estimates of fatty liver, the fatty liver index (FLI) and liver fat percentage (LF%). RESULTS IMT, FLI, LF%, presence of the metabolic syndrome, impaired glucose regulation, insulin and triglycerides increased across sCD36 quartiles (Q2-Q4), whereas adiponectin and M/I decreased (P ≤ 0.01). sCD36 was lower in women than in men (P = 0.045). Log sCD36 showed a bimodal distribution, and amongst subjects with sCD36 within the log-normal distribution (log-normal population, n = 1029), sCD36 was increased in subjects with impaired glucose regulation (P = 0.045), metabolic syndrome (P = 0.006) or increased likelihood of fatty liver (P < 0.001). sCD36 correlated significantly with insulin, triglycerides, M/I and FLI (P < 0.05) after adjustment for study centre, gender, age, glucose tolerance status, smoking habits and alcohol consumption. In the log-normal population, these relationships were stronger than in the total study population and, additionally, sCD36 was significantly associated with LF% and IMT (P < 0.05). CONCLUSIONS In this cross-sectional study of nondiabetic subjects, sCD36 was significantly associated with indices of insulin resistance, carotid atherosclerosis and fatty liver. Prospective studies are needed to further evaluate the role of sCD36 in the inter-relationship between atherosclerosis, fatty liver and insulin resistance.
Collapse
Affiliation(s)
- A Handberg
- Department of Clinical Biochemistry, Aarhus Hospital and Aalborg Hospital, Aarhus University Hospital, Aarhus, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Galkina EV, Butcher M, Keller SR, Goff M, Bruce A, Pei H, Sarembock IJ, Sanders JM, Nagelin MH, Srinivasan S, Kulkarni RN, Hedrick CC, Lattanzio FA, Dobrian AD, Nadler JL, Ley K. Accelerated atherosclerosis in Apoe-/- mice heterozygous for the insulin receptor and the insulin receptor substrate-1. Arterioscler Thromb Vasc Biol 2011; 32:247-56. [PMID: 22199371 DOI: 10.1161/atvbaha.111.240358] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Prediabetic states are associated with accelerated atherosclerosis, but the availability of mouse models to study connections between these diseases has been limited. The aim of this study was to test the selective role of impaired insulin receptor/insulin receptor substrate-1 signaling on atherogenesis. METHODS AND RESULTS To address the effects of impaired insulin signaling associated with hyperinsulinemia on atherosclerosis in the absence of obesity and hyperglycemia, we generated insulin receptor (Insr)/insulin receptor substrate-1 (Insr1) double heterozygous apolipoprotein (Apoe)-knockout mice (Insr(+/-)Irs1(+/-)Apoe(-/-)) mice. Insr(+/-)Irs1(+/-)Apoe(-/-) mice fed a Western diet for 15 weeks showed elevated levels of fasting insulin compared to Insr(+/+)Irs1(+/+)Apoe(-/-) mice. There were no significant differences in glucose, triglyceride, HDL, VLDL, cholesterol levels or free fatty acid in the plasma of Insr(+/-)Irs1(+/-)Apoe(-/-) and Insr(+/+)Irs1(+/+)Apoe(-/-) mice. Atherosclerotic lesions were increased in male (brachiocephalic artery) and female (aortic tree) Insr(+/-)Irs1(+/-)Apoe(-/-) compared to Insr(+/+)Irs1(+/+)Apoe(-/-) mice. Bone marrow transfer experiments demonstrated that nonhematopoietic cells have to be Insr(+/-)Irs1(+/-) to accelerate atherosclerosis. Impaired insulin signaling resulted in decreased levels of vascular phospho-eNOS, attenuated endothelium-dependent vasorelaxation and elevated VCAM-1 expression in aortas of Insr(+/-)Irs1(+/-)Apoe(-/-) mice. In addition, phospho-ERK and vascular smooth muscle cell proliferation were significantly elevated in aortas of Insr(+/-)Irs1(+/-)Apoe(-/-) mice. CONCLUSIONS These results demonstrate that defective insulin signaling is involved in accelerated atherosclerosis in Insr(+/-)Irs1(+/-)Apoe(-/-) mice by promoting vascular dysfunction and inflammation.
Collapse
Affiliation(s)
- Elena V Galkina
- Eastern Virginia Medical School, P.O. Box 1980, Norfolk, VA 23501, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Mita T, Azuma K, Goto H, Jin WL, Arakawa M, Nomiyama T, Suzuki R, Kubota N, Tobe K, Kadowaki T, Fujitani Y, Hirose T, Kawamori R, Watada H. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem Biophys Res Commun 2011; 415:545-50. [PMID: 22074825 DOI: 10.1016/j.bbrc.2011.10.086] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2011] [Accepted: 10/18/2011] [Indexed: 02/02/2023]
Abstract
The aim of this study was to investigate the role of insulin receptor substrate-2 (IRS-2) mediated signal in macrophages on the accumulation of macrophages in the vascular wall. Mice transplanted with IRS-2(-/-) bone marrow, a model of myeloid cell restricted defect of IRS-2, showed accumulation of monocyte chemoattractant protein-1-expressing macrophages in the vascular wall. Experiments using cultured peritoneal macrophages showed that IRS-2-mediated signal pathway stimulated by physiological concentrations of insulin, not by IL-4, contributed to the suppression of monocyte chemoattractant protein-1 expression induced by lipopolysaccharide. Our data indicated that IRS-2 deficiency in macrophages enhanced their accumulation in the vascular wall accompanied by increased expression of proinflammatory mediators in macrophages. These results suggest a role for insulin resistance in macrophages in early atherosclerogenesis.
Collapse
Affiliation(s)
- Tomoya Mita
- Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Jiménez-Navarro MF, Bueno H, Alvarez-Sala L, Rodríguez-Losada N, Andrés V, González-Navarro H. Insulin receptor substrate-1 expression is increased in circulating leukocytes of patients with acute coronary syndrome. ISRN CARDIOLOGY 2011; 2011:740585. [PMID: 22347652 PMCID: PMC3262509 DOI: 10.5402/2011/740585] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 04/20/2011] [Indexed: 12/02/2022]
Abstract
The mechanisms underlying the increased risk of cardiovascular disease associated with diabetes mellitus (DM) are not fully defined. Insulin resistance in human metabolic syndrome patients is associated with decreased expression of the insulin receptor substrate-2- (Irs2-) AKT2 axis in mononuclear leukocytes (MLs). Moreover, acute coronary syndrome (ACS) has been linked through genome-wide association studies to the 2q36-q37.3 locus, which contains the Irs1 gene. Here, we investigated the expression of insulin-signaling pathway genes in MLs from patients with DM, ACS, and ACS plus DM. Quantitative real-time PCR expression studies showed no differences in the mRNA levels of Irs2, Akt2, and Akt1 among all patients. However, Irs1 mRNA expression was significantly increased in patients with ACS—diabetics and nondiabetics—compared with diabetic patients without ACS (P < .02 and P < .005, resp.). The present study reveals for the first time an association between increased Irs1 mRNA levels in MLs of patients with ACS which is not related to DM.
Collapse
Affiliation(s)
- Manuel F Jiménez-Navarro
- Department of Cardiology, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain
| | | | | | | | | | | |
Collapse
|
37
|
Zhao G, Shaik RS, Zhao H, Beagle J, Kuo S, Hales CA. Low molecular weight (LMW) heparin inhibits injury-induced femoral artery remodeling in mouse via upregulating CD44 expression. J Vasc Surg 2011; 53:1359-1367.e3. [PMID: 21276692 DOI: 10.1016/j.jvs.2010.11.048] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Revised: 11/01/2010] [Accepted: 11/06/2010] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The mechanism of postangioplasty restenosis remains poorly understood. Low molecular weight (LMW) heparin has been shown to inhibit the proliferation of vascular smooth muscle cells (VSMCs), which is the principal characteristic of restenosis. Studies have shown that LMW heparin could bind to CD44. We hypothesized that LMW heparin might modulate CD44 expression thereby decreasing vascular remodeling. METHODS Vascular remodeling was induced in CD44(+/+) and CD44(-/-) mice and treated with LMW heparin. The arteries were harvested for histologic assessment and determination of CD44 expression. Bone marrow transplantation was introduced to further explore the role and functional sites of CD44. Effects of LMW heparin on growth capacity, CD44 expression were further studied using the cultured mouse VSMCs. RESULTS Transluminal injury induced remarkable remodeling in mouse femoral artery (sham wall thickness percentage [WT%]: 3.4 ± 1.2% vs injury WT%: 31.8 ± 4.7%; P < .001). LMW heparin reduced the remodeling significantly (WT%: 17.8 ± 3.5%, P < .005). CD44(-/-) mice demonstrated considerably thicker arterial wall remodeling (WT%: 46.2 ± 7.6%, P = .0035), and CD44-chimeric mice exhibited equal contributions of the local and circulating CD44 signal to the neointima formation. LMW heparin markedly upregulated CD44 expression in the injured femoral arteries. In vitro, LMW heparin decreased mouse VSMC growth capacity and upregulated its CD44 expression simultaneously in a dose-dependent and time-dependent manner, which could be partially blocked by CD44 inhibitor. CONCLUSIONS LMW heparin inhibits injury-induced femoral artery remodeling, at least partially, by upregulating CD44 expression.
Collapse
MESH Headings
- Animals
- Bone Marrow Transplantation
- Cell Proliferation/drug effects
- Cells, Cultured
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Femoral Artery/drug effects
- Femoral Artery/immunology
- Femoral Artery/injuries
- Femoral Artery/pathology
- Heparin, Low-Molecular-Weight/pharmacology
- Hyaluronan Receptors/genetics
- Hyaluronan Receptors/metabolism
- Hyperplasia
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/immunology
- Muscle, Smooth, Vascular/injuries
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/immunology
- Myocytes, Smooth Muscle/pathology
- Time Factors
- Tunica Intima/drug effects
- Tunica Intima/immunology
- Tunica Intima/injuries
- Tunica Intima/pathology
- Up-Regulation
- Vascular System Injuries/drug therapy
- Vascular System Injuries/genetics
- Vascular System Injuries/immunology
- Vascular System Injuries/pathology
Collapse
Affiliation(s)
- Gaofeng Zhao
- Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | | | | | | | | | | |
Collapse
|
38
|
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010; 11:379-89. [PMID: 20444418 PMCID: PMC3020149 DOI: 10.1016/j.cmet.2010.03.013] [Citation(s) in RCA: 225] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2009] [Revised: 02/01/2010] [Accepted: 03/16/2010] [Indexed: 12/21/2022]
Abstract
To determine whether insulin action on endothelial cells promotes or protects against atherosclerosis, we generated apolipoprotein E null mice in which the insulin receptor gene was intact or conditionally deleted in vascular endothelial cells. Insulin sensitivity, glucose tolerance, plasma lipids, and blood pressure were not different between the two groups, but atherosclerotic lesion size was more than 2-fold higher in mice lacking endothelial insulin signaling. Endothelium-dependent vasodilation was impaired and endothelial cell VCAM-1 expression was increased in these animals. Adhesion of mononuclear cells to endothelium in vivo was increased 4-fold compared with controls but reduced to below control values by a VCAM-1-blocking antibody. These results provide definitive evidence that loss of insulin signaling in endothelium, in the absence of competing systemic risk factors, accelerates atherosclerosis. Therefore, improving insulin sensitivity in the endothelium of patients with insulin resistance or type 2 diabetes may prevent cardiovascular complications.
Collapse
|
39
|
González-Navarro H, Abu Nabah YN, Vinué A, Andrés-Manzano MJ, Collado M, Serrano M, Andrés V. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 2010; 55:2258-68. [PMID: 20381282 DOI: 10.1016/j.jacc.2010.01.026] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2009] [Revised: 01/14/2010] [Accepted: 01/18/2010] [Indexed: 01/22/2023]
Abstract
OBJECTIVES The goal of this study was to investigate the role in atherosclerosis of the tumor suppressor protein ARF (human p14(ARF), mouse p19(ARF)) encoded by the CDKN2A gene. BACKGROUND Atherosclerosis is characterized by excessive proliferation and apoptosis, 2 cellular processes regulated by CDKN2A. Although recent genome-wide association studies have linked atherosclerotic diseases to a genomic region in human chromosome 9p21 near the CDKN2A locus, the mechanisms underlying this gene-disease association remain undefined, and no causal link has been established between CDKN2A and atherosclerosis. METHODS Atherosclerosis-prone apolipoprotein E (apoE)-null and doubly deficient apoE-p19(ARF) mice were fed an atherogenic diet and sacrificed to quantify atherosclerosis burden in whole-mounted aortas and in aortic cross-sections. Proliferation and apoptosis were investigated in atherosclerotic lesions and in primary cultures of macrophages and vascular smooth muscle cells obtained from both groups of mice. RESULTS Genetic disruption of p19(ARF) in apoE-null mice augments aortic atherosclerosis without affecting body weight, plasma lipoproteins, or plaque's proliferative activity. Notably, p19(ARF) deficiency significantly attenuates apoptosis both in atherosclerotic lesions and in cultured macrophages and vascular smooth muscle cells, 2 major cellular constituents of atheromatous plaques. CONCLUSIONS Our findings establish a direct link between p19(ARF), plaque apoptosis, and atherosclerosis, and suggest that human genetic variants associated to diminished CDKN2A expression may accelerate atherosclerosis by limiting plaque apoptosis.
Collapse
Affiliation(s)
- Herminia González-Navarro
- Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia , Spanish Council for Scientific Research, Valencia, Spain
| | | | | | | | | | | | | |
Collapse
|
40
|
Johnson LA, Maeda N. Macrovascular complications of diabetes in atherosclerosisprone mice. Expert Rev Endocrinol Metab 2010; 5:89-98. [PMID: 30934383 DOI: 10.1586/eem.09.66] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The well-established relationship between diabetes and cardiovascular complications, combined with the rapidly increasing prevalence of diabetes, has created a pressing need for better understanding of the mechanisms of diabetic atherosclerosis. Multiple metabolic and diabetes-specific factors have been associated with accelerated atherosclerosis, including dyslipidemia, oxidative stress, inflammation, vascular cell dysfunction and coagulopathy. This discussion highlights selected studies in which researchers have employed mouse models of diabetic atherosclerosis in an attempt to examine these mechanisms and test potential therapeutic and preventative measures.
Collapse
Affiliation(s)
- Lance A Johnson
- a Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA.
| | - Nobuyo Maeda
- b Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA.
| |
Collapse
|